Kezar bags a $50M B round in wake of PhIa study; Bay­er kicks back a part­nered drug

→ Right on the heels of what it calls a suc­cess­ful Phase Ia study for its im­muno­pro­tea­some in­hibitor, South San Fran­cis­co-based Kezar Life Sci­ences has at­tract­ed a big syn­di­cate for a $50 mil­lion B round. Cor­morant As­set Man­age­ment and Morn­ing­side Ven­ture led the round, which in­cludes new in­vestors like Cowen Health­care In­vest­ments, Pap­pas Ven­tures, Qim­ing Ven­ture Part­ners and Bay City Cap­i­tal. They were joined by ex­ist­ing in­vestors EcoR1 Cap­i­tal, Omega Funds, and Aju IB In­vest­ment. Kezar has now raised a to­tal of $73 mil­lion since its in­cep­tion in 2015.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER